Skip to main content
SpringerLink
Log in

Camptothecins in the Treatment of Primary Brain Tumors

  • Chapter
Camptothecins in Cancer Therapy

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

  • 740 Accesses

Abstract

The number of new cases of primary malignant brain tumors diagnosed in 2003 more than double the number of diagnosed cases of Hodgkin’s disease, approximately 13,100 deaths were estimated to have occurred as a result of primary cancer of the central nervous system (CNS). Metastases to the brain from a systemic primary cancer are even more common. One estimate suggests that more than 100,000 patients per year die with symptomatic intracranial metastases. In addition, if benign cases are considered, approximately 36,000 brain tumors would have been diagnosed in 2002. The age- and sex-adjusted incidence of primary tumors of the CNS is estimated to be approximately 19 per 100,000 persons per year (11.8 per 100,000 for symptomatic tumors and 7.3 per 100,000 for asymptomatic tumors) (1).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. DeAngelis L. 2001 Brain tumors. N Engl J Med 344:114–123.

    Google Scholar 

  2. Radhakrishnan K, Mokri B, Parisi JE, et al. 1995 The trends in incidence of brain tumors in the population of Rochester, Minnesota. Ann Neurol 37:67–73.

    Google Scholar 

  3. Wall ME, Wani MC, Cook CE, Palmer KH. 1966 Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 88:3888–3890.

    Google Scholar 

  4. Kepler JA, Wani MC, McNaull JN, Wall ME, Levine SG. 1969 Plant antitumor agents. IV. An approach toward the synthesis of camptothecin. J Org Chem 34:3853–3858.

    Google Scholar 

  5. Gottlieb JA, Guarino AM, Call JB, Oliverio VT, Block JB. 1970 Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother Rep 54:461–470.

    Google Scholar 

  6. Muggia FM, Creaven PJ, Hansen HH, Cohen MH, Selawry OS. 1972 Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother Rep 56:515–521.

    Google Scholar 

  7. Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG. 1972 Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 56:95–101.

    Google Scholar 

  8. Xu B. U.S./China Pharmacology Symposium. Burns JJ, Tsuchiatani PJ. 1980.

    Google Scholar 

  9. Hsiang YH, Hertzberg R, Hecht S, Liu LF. 1985 Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260:14873–14878.

    Google Scholar 

  10. Konstadoulakis MM, Antonakis PT, Tsibloulis BG, et al. 2001 A phase II study of 9-nitrocamptothecin in patients with advanced pancreatic adenocarcinoma. Cancer Chemother Pharmacol 48:417–420.

    Google Scholar 

  11. Giovanella BC, Stehlin JS, Hinz HR, Kozielski AJ, Harris NJ, Vardeman DM. 2002 Preclinical evaluation of the anticancer activity and toxicity of 9-nitro-20(S)-camptothecin (Rubitecan). Int J Oncol 20:81–88.

    Google Scholar 

  12. Han Z, Wyche JH, Sands H, Pantazis P. 2001 9-Nitrocamptothecin is an effective drug for the treatment of human lung tumors: comparison of in vitro and in vivo studies. Anticancer Res 21:1823–1827.

    Google Scholar 

  13. Verschraegen CF, Vincent M, Abbruzzese JL, et al. 2000 Phase I study of 9-nitro-20(S)-camptothecin in combination with cisplatin for patients with advanced malignancies. Ann NY Acad Sci 922:345–348.

    Google Scholar 

  14. Hinz HR, Harris NJ, Natelson EA, Giovanella BC. 1994 Pharmacokinetics of the in vivo and in vitro conversion of 9-nitro-20(S)-camptothecin to 9-amino-20(S)-camptothecin in humans, dogs, and mice. Cancer Res 54:3096–3100.

    Google Scholar 

  15. Pantazis P, Kozielski AJ, Vardeman DM, Petry ER, Giovanella BC. 1993 Efficacy of camptothecin congeners in the treatment of human breast carcinoma xenografts. Oncol Res 5:273–281.

    Google Scholar 

  16. Takimoto CH, Thomas R. 2000 The clinical development of 9-aminocamptothecin. Ann NY Acad Sci 922:224–236.

    Google Scholar 

  17. Holthuis JJM, Postmus PE, van Oort WJ. 1986 Pharmacokinetics of high dose etoposide (VP16-213). Eur J Cancer Clin Oncol 22:1149–1155.

    Google Scholar 

  18. Liu LF, Desai SD, Li TK, Mao Y, Sun M, Sim SP. 2000 Mechanism of action of camptothecin. Ann NY Acad Sci 922:1–10.

    Google Scholar 

  19. Champoux JJ. 2001 DNA topoisomerases: structure, function, and mechanism. 2001 Annu Rev Biochem 70:369–4

    Google Scholar 

  20. Stewart C. Topoisomerase I interactive agents. 2001 Cancer Chemother Biol Response Modif 19:85–128.

    Google Scholar 

  21. Houghton PJ, Chesire PJ, Myers L, Stewart CF, Synold TW, Houghton JA. 1992 Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother Pharmacol 31:229–239.

    Google Scholar 

  22. Houghton PJ, Cheshire PJ, Hallman JD, et al. 1995 Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 36:393–403.

    Google Scholar 

  23. Houghton PJ, Stewart CF, Zamboni WC, Thompson J, Danks MK, Houghton JA. 1996 Schedule dependent efficacy of camptothecins in models of human cancer. NY Acad Sci 803:188–201.

    Google Scholar 

  24. Zamboni WC, Stewart CF, Thompson J, et al. 1998 Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts. J Natl Cancer Inst 90:505–511.

    Google Scholar 

  25. El Gizawy SA, Hedaya MA. 1999 Comparative brain tissue distribution of camptothecin and topotecan in the rat. Cancer Chemother Pharmacol 43:364–370.

    Google Scholar 

  26. Straathof CS, van den Bent MJ, Loos WJ, Vecht CJ, Schellens JH. 1999 The accumulation of topotecan in 9L glioma and in brain parenchyma with and without dexamethasone administration. J Neurooncol 42:117–122.

    Google Scholar 

  27. Pollina J, Plunkett RJ, Ciesielski MJ, et al. 1998 Intratumoral infusion of topotecan prolongs survival in the nude rat intracranial U87 human glioma model. J Neurooncol 39:217–225.

    Google Scholar 

  28. Blaney SM, Cole DE, Balis FM, Godwin K, Poplack DG. 1993 Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates. Cancer Res 53:725–727.

    Google Scholar 

  29. Zamboni WC, Gajjar AJ, Mandrell TD, et al. 1998 A four-hour topotecan infusion achieves cytotoxic exposure throughout the neuraxis in the nonhuman primate model: implications for treatment of children with metastatic medulloblastoma. Clin Cancer Res 4:2537–2544.

    Google Scholar 

  30. Danks MK, Pawlik CA, Whipple DO, Wolverton JS. 1997 Intermittent exposure of medulloblastoma cells to topotecan produces growth inhibition equivalent to continuous exposure. Clin Cancer Res 3:1731–1738.

    Google Scholar 

  31. Pawlik CA Houghton PJ Stewart CF Cheshire PJ Richmond LB Danks MK. 1998 Effective schedules of exposure of medulloblastoma and rhabdomyosarcoma xenografts to topotecan correlate with in vitro assays. Clin Cancer Res 4:1995–2002

    Google Scholar 

  32. Blaney SM, Takimoto C, Murry DJ, et al. 1998 Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates. Cancer Chemother Pharmacol 41:464–468.

    Google Scholar 

  33. Hare CB, Elion GB, Houghton PJ, et al. 1997 Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyl-oxycamptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol 39:187–191.

    Google Scholar 

  34. Vassal G, Boland I, Santos A, et al. 1997 Potent therapeutic activity of irinotecan (CPT-11) and its schedule dependency in medulloblastoma xenografts in nude mice. Int J Cancer 73:156–163.

    Google Scholar 

  35. Friedman HS, Castellino RC, Elion GB, et al. 2000 Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts. Cancer Chemother Pharmacol 45:345–349.

    Google Scholar 

  36. Coggins CA, Elion GB, Houghton PJ, et al. 1998 Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents. Cancer Chemother Pharmacol 41:485–490.

    Google Scholar 

  37. Houghton PJ, Stewart CF, Cheshire PJ, et al. 2000 Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models. Clin Cancer Res 6:4110–4118.

    Google Scholar 

  38. Pourquier P, Waltman JL, Urasaki Y, et al. 2001 Topoisomerase I-mediated cytotoxicity of N-methyl-N′-nitro-N-nitrosoguanidine: trapping of topoisomerase I by the O6-methylguanine. Cancer Res 61:53–58.

    Google Scholar 

  39. Keir ST, Hausheer F, Lawless AA, Bigner DD, Friedman HS. 2001 Therapeutic activity of 7-[(2-trimethylsilyl)ethyl)]-20 (S)-camptothecin against central nervous system tumor-derived xenografts in athymic mice. Cancer Chemother Pharmacol 48:83–87.

    Google Scholar 

  40. Tsai TH, Chen YF, Chou CJ, Chen CF. 2000 Measurement and pharmacokinetics of unbound 20(S)-camptothecin in rat blood and brain by microdialysis coupled to microbore liquid chromatography with fluorescence detection. J Chromatogr A 870:221–226.

    Google Scholar 

  41. Pollack IF, Erff M, Bom D, Burke TG, Strode JT, Curran DP. 1999 Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo. Cancer Res 59:4898–4905.

    Google Scholar 

  42. Lavergne O, Lesueur-Ginot L, Pla RF, et al. 1998 Homocamptothecins: synthesis and antitumor activity of novel E-ring-modified camptothecin analogues. J Med Chem 41:5410–5419.

    Google Scholar 

  43. Lavergne O, Harnett J, Rolland A, et al. 1999 BN 80927: a novel homocamptothecin with inhibitory activities on both topoisomerase I and topoisomerase II. Bioorg Med Chem Lett 9:2599–2602.

    Google Scholar 

  44. Lesueur-Ginot L, Demarquay D, Kiss R, et al. 1999 Homocamptothecin, an E-ring modified camptothecin with enhanced lactone stability, retains topoisomerase I-targeted activity and antitumor properties. Cancer Res. 59:2939–2943.

    Google Scholar 

  45. Bailly C, Lansiaux A, Dassonneville L, et al. 1999 Homocamptothecin, an E-ring-modified camptothecin analogue, generates new topoisomerase I-mediated DNA breaks. Biochemistry (Mosc) 38:15556–15563.

    Google Scholar 

  46. Frangoul H, Ames MM, Mosher RB, et al. 1999 Phase I study of topotecan administered as a 21-day continous infusion in children with recurrent solid tumors: a report from the Children’s Cancer Group. Clin Cancer Res 5:3956–3962.

    Google Scholar 

  47. Stewart CF, Gajjar AJ, Heideman RL, Houghton PJ. 1998 Penetration of topotecan into cerebrospinal fluid after intravenous injection. Onkologie 21:22–24.

    Google Scholar 

  48. Stewart CF, Baker SD, Heideman RL, Jones D, Crom WR, Pratt CB. 1994 Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity. J Clin Oncol 12:1946–1954.

    Google Scholar 

  49. Zamboni WC, Stewart CF, Thompson J, et al. 1998 Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts. J Natl Cancer Inst 90:505–511.

    Google Scholar 

  50. Tubergen DG, Stewart CF, Pratt CB, et al. 1996 Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: A Pediatric Oncology Group Study. J Ped Hematol Oncol 18:352–361.

    Google Scholar 

  51. Athale UH, Stewart C, Kuttesch JF, et al. 2002 Phase I study of combination topotecan and carboplatin in pediatric solid tumors. J Clin Oncol 20:88–95.

    Google Scholar 

  52. Kushner BH, Cheung NK, Kramer K, Dunkel IJ, Calleja E, Boulad F. 2001 Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults. Bone Marrow Transplant 28:551–556.

    Google Scholar 

  53. Friedman HS, Kerby T, Fields S, et al. 1999 Topotecan treatment of adults with primary malignant glioma. The Brain Tumor Center at Duke. Cancer 85:1160–1165.

    Google Scholar 

  54. Zamboni WC, Gajjar AJ, Heideman RL, et al. 1998 Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma. Clin Cancer Res 4:783–789.

    Google Scholar 

  55. Macdonald D, Cairncross G, Stewart D, et al. 1996 Phase II study of topotecan in patients with recurrent malignant glioma. National Clinical Institute of Canada Clinical Trials Group. Ann Oncol 7:205–207.

    Google Scholar 

  56. Burch PA, Bernath AM, Cascino TL, et al. 2000 A North Central Cancer Treatment Group phase II trial of topotecan in relapsed gliomas. Invest New Drugs 18:275–280.

    Google Scholar 

  57. Nitschke R, Parkhurst J, Sullivan J, Harris MB, Bernstein M, Pratt C. 1998 Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group phase II study. J Pediatr Hematol Oncol 20:315–358.

    Google Scholar 

  58. Blaney SM, Needle MN, Gillespie A, et al. 1998 Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children’s Cancer Group Study. Clin Cancer Res 4:357–360.

    Google Scholar 

  59. Blaney SM, Phillips PC, Packer RJ, et al. 1996 Phase II evaluation of topotecan for pediatric central nervous system tumors. Cancer 78:527–531.

    Google Scholar 

  60. Kadota RP, Stewart CF, Horn M, et al. 1999 Topotecan for the treatment of recurrent or progressive central nervous system tumors—a pediatric oncology group phase II study. J Neurooncol 43:43–47.

    Google Scholar 

  61. Stewart CF, Iacono LC, Chintagumpala M, Kellie SJ, Ashley D, Zamboni WE, et al. 2004 Results of a Phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor (PNET). J Clin Oncol 22:3357–3365.

    Google Scholar 

  62. Fisher BJ, Scott C, Macdonald DR, Coughlin C, Curran WJ. 2001 Phase I study of topotecan plus cranial radiation for glioblastoma multiforme: results of Radiation Therapy Oncology Group Trial 9507. J Clin Oncol 19:1111–1117.

    Google Scholar 

  63. Gross MW, Altscher R, Brandtner M, et al. 2001 Acute toxicity and changes in quality of life during a combined radio-chemotherapy of glioblastomas with topotecan (Hycamtin). Strahlenther Onkol 177:656–661.

    Google Scholar 

  64. Sanghavi SN, Needle MN, Krailo MD, Geyer JR, Ater J, Mehta MP. 2003 A phase I study of topotecan as a radiosensitizer for brainstem glioma of childhood: first report of the Children’s Cancer Group-0952. Neurooncol 5:8–13.

    Google Scholar 

  65. Wagner S, Erdlenbruch B, Langler A, et al. 2004 Oral topotecan in children with recurrent or progressive high-grade glioma: a Phase I/II study by the German Society for Pediatric Oncology and Hematology. Cancer 100:1750–1757.

    Google Scholar 

  66. Friedman HS, Petros WP, Friedman AH, et al. 1999 Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 17:1516–1525.

    Google Scholar 

  67. Cloughesy TF, Filka E, Nelson G, et al. 2002 Irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Am J Clin Oncol 25:204–208.

    Google Scholar 

  68. Crews K, Stewart CF, Jones-Wallace D, et al. 2002 Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy. Clin Cancer Res 8:2202–2209.

    Google Scholar 

  69. Blaney S, Berg SL, Pratt C, et al. 2001 A phase I study of irinotecan in pediatric patients: a pediatric oncology group study. Clin Cancer Res 7:32–37.

    Google Scholar 

  70. Turner CD, Gururangan S, Eastwood J, et al. 2002 Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience. Neurooncol 4:102–108.

    Google Scholar 

  71. Raymond E, Fabbro M, Boige V, et al. 2003 Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naive patients with glioblastoma. Ann Oncol 14:603–614.

    Google Scholar 

  72. Hochberg F, Grossman SA, Mikkelsen T, Glantz M, Fisher JD, Piantadosi S. 2000 Lack of efficacy of 9-aminocamptothecin in adults with newly diagnosed glioblastoma multiforme and recurrent high-grade astrocytoma. NABTT CNS Consortium. Neurooncol 2:29–33.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, TN

    Clinton F. Stewart PharmD

  2. Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY

    Markos Leggas PhD

  3. Brain Tumor Center, Duke University Medical Center, Durham, NC

    Henry S. Friedman MD

Authors
  1. Clinton F. Stewart PharmD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Markos Leggas PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Henry S. Friedman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pharmacy Practice and Science, College of Pharmacy, University of Kentucky, Lexington, KY

    Val R. Adams PharmD

  2. Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY

    Thomas G. Burke PhD

  3. Experimental Therapeutics Program, Lucille P. Markey Cancer Center, University of Kentucky Medical Center, University of Kentucky, Lexington, KY

    Thomas G. Burke PhD

  4. Tigen Pharmaceuticals Inc., Lexington, KY

    Thomas G. Burke PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Stewart, C.F., Leggas, M., Friedman, H.S. (2005). Camptothecins in the Treatment of Primary Brain Tumors. In: Adams, V.R., Burke, T.G. (eds) Camptothecins in Cancer Therapy. Cancer Drug Discovery and Development. Humana Press. https://doi.org/10.1385/1-59259-866-8:343

Download citation

  • DOI: https://doi.org/10.1385/1-59259-866-8:343

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-027-4

  • Online ISBN: 978-1-59259-866-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation